Format

Send to

Choose Destination
Expert Rev Anticancer Ther. 2018 Jan;18(1):91-100. doi: 10.1080/14737140.2018.1409626. Epub 2017 Dec 15.

Cardiovascular mortality trends in non-Hodgkin's lymphoma: a population-based cohort study.

Author information

1
a Faculty of Medicine , Minia University , Minia , Egypt.
2
b University of Medicine and Pharmacy , Ho Chi Minh City , Vietnam.
3
c Evidence Based Medicine Research Group & Faculty of Applied Sciences , Ton Duc Thang University , Ho Chi Minh City , Vietnam.
4
d Department of Clinical Product Development, Institute of Tropical Medicine (NEKKEN), Leading Graduate School Program, and Graduate School of Biomedical Sciences , Nagasaki University , Nagasaki , Japan.

Abstract

BACKGROUND:

Non-Hodgkin's lymphoma (NHL) survivors are at a higher risk of cardiovascular diseases (CVDs).

METHODS:

A population-based study was conducted to investigate the cardiovascular mortality trends to identify NHL survivors at the highest risk.

RESULTS:

The CVDs mortality was the second most common cause of death (13.07%) after NHL. There were more patients ≥ 60 years old in the cardiovascular group (87.2%), P < 0.001. Patients who died from CVDs had the best survival while patients who died from NHL had a significantly lower mean survival. The overall survival rate was 92.4%. Consistently, older age, unmarried, male patients, not recently diagnosed with NHL and not receiving radiation and/or surgery were associated with a worse survival across all models. The black race and stage IV only had a worse cardiovascular specific survival (CVSS).

CONCLUSIONS:

Although the CVSS improved over time, the mortality from the CVDs is still the second most common cause of death after NHL. Older age, not married, black, male patients, not recently diagnosed with NHL, with an advanced stage and not receiving radiation and/or surgery were associated with a worse survival. Risk factor modification along with CVDs screening should be intensified in NHL patients with these mortality predictors.

KEYWORDS:

Non-Hodgkin’s lymphoma; SEER; cardiovascular; mortality; survival

PMID:
29192533
DOI:
10.1080/14737140.2018.1409626
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center